- Home
- ROIV vs FFIV Comparison
ROIV vs FFIV Comparison
Compare ROIV & FFIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | FFIV |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Communications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 21.6B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ROIV | FFIV |
|---|---|---|
| Price | $28.21 | $409.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 11 |
| Target Price | $28.94 | ★ $312.88 |
| AVG Volume (30 Days) | ★ 5.8M | 647.9K |
| Earning Date | 05-28-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.56 |
| EPS | N/A | ★ 5.68 |
| Revenue | $8,260,000.00 | ★ $3,088,072,000.00 |
| Revenue This Year | N/A | $8.00 |
| Revenue Next Year | $744.61 | $3.27 |
| P/E Ratio | ★ N/A | $69.65 |
| Revenue Growth | N/A | ★ 9.66 |
| 52 Week Low | $10.71 | $223.76 |
| 52 Week High | $32.79 | $399.59 |
Technical Indicators
Market Signals| Indicator | ROIV | FFIV |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 77.22 |
| Support Level | $26.95 | $283.74 |
| Resistance Level | $30.10 | N/A |
| Average True Range (ATR) | 1.10 | 11.91 |
| MACD | -0.15 | 0.61 |
| Stochastic Oscillator | 7.69 | 98.40 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.